Ypsomed crece intensamente con productos propios

Noticias Ypsomed España

Burgdorf - Ypsomed incrementó sus ventas en 45.3 millones de francos suizos en el primer semestre de 2018/19. El resultado operativo (BAII) asciende a 68.4 millones de francos suizos. Este resultado incluye una compensación de 49.8 millones de francos suizos de Insulet Corp. en términos de ingresos y ganancias. Las estrategias de crecimiento con productos propios en expansión, innovación y producción se continuarán aplicando con determinación. La bomba de insulina mylife YpsoPump se está desarrollando con éxito, superando las expectativas.

Leer más...

Ypsomed teams up with Philips for the development of its new digital services to simplify medication adherence monitoring

Press Releases Ypsomed Group

Burgdorf and Eindhoven (NL) – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.

Leer más...

Ypsomed partners with JDRF

Ypsomed partners with JDRF to develop new open technologies for next-generation automated insulin delivery (AID) systems

Press Releases Ypsomed Group

Burgdorf/New York – JDRF, the leading global organization funding type 1 diabetes (T1D) research, has announced a partnership with Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, as part of JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative. The objective of the project is the development and regulatory approval of the next-generation mylife™ YpsoPump® insulin pump supporting incorporation into an automated insulin delivery (AID) system via open-protocol communication with third-party smartphone-based apps and/or other devices.

Leer más...

Topping-out ceremony at the new Ypsomed site in Schwerin
After completion of the building shell in the coming weeks, the interior work of the production plant will now begin.

Topping-out ceremony at the new Ypsomed site in Schwerin

Press Releases Ypsomed Group

Burgdorf/Schwerin - The topping-out ceremony for Ypsomed's new production plant took place on 28 June 2018. The Swiss medical technology company is building a new production plant in Schwerin's industrial park, creating around 150 new jobs in the region in the coming years. The new production plant will start operations in summer 2019.

Leer más...

Change in the Board of Directors of the Ypsomed Group

Press Releases Ypsomed Group

Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until March 2018 he was President and CEO of Boehringer Ingelheim USA. Paul Fonteyne follows Prof. em. Dr. Norbert Thom, who resigned at the 2018 Annual General Meeting.

Leer más...